Small Pharma Inc V.DMT

Healthcare

Small Pharma Inc. is a biotechnology company focused on short-duration psychedelic therapies for mental health conditions. The Company is focused on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions that are scalable, commercially differentiated, and conveniently dosed, with the goal of addressing key unmet needs in the treatment of depression. It has a portfolio of clinical-stage dimethyltryptamine (DMT)-based assets, SPL026 and SPL028. It has a pipeline of proprietary preclinical assets. Its clinical-stage program, SPL026, a first-generation DMT molecule, has shown proof-of-concept for the potential treatment of MDD. In a Phase IIa study, IV SPL026 demonstrated a rapid and durable antidepressant effect, as well as a favorable safety and tolerability profile. Small Pharma is also advancing SPL028, a second-generation injectable deuterated DMT molecule, in a Phase I trial.

TSXV:DMT - Post by User

Small Pharma Inc

<< Previous

Bullboard Posts

Next >>

Post by GillRipperon Aug 28, 2023 10:02am

134 Views

Post# 35607922

Halt?

Canadian Investment Regulatory Organization Trading Halt - DMT

2023-08-28 09:29 ET - News Release

VANCOUVER, BC, Aug. 28, 2023 /CNW/ - The following issues have been halted by CIROCompany: Small Pharma Inc. TSX-Venture Symbol: DMT All Issues: Yes

Reason: Pending News

Halt Time (ET): 9:17 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023